--- title: KRASmut PDO SCREEN description: Test the efficacy of compounds in a pan-KRAS mutant organoid screening. Accelerate drug development for colorectal, lung, and pancreatic cancers. --- [![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/) ![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png) ![kras-pink-teal](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/kras-pink-teal.png?width=518&height=508&name=kras-pink-teal.png) **TARGET KRAS WITH CONFIDENCE** # **PAN-KRAS PDO Screen** Test the efficacy of your compound(s) in a panel of 25 patient-derived organoids representing colorectal, lung, and pancreatic cancer ![lung-cancer](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/colorectal-cancer-icon.png?width=180&name=colorectal-cancer-icon.png) #### Colorectal cancer ![lung-cancer](https://resources.huborganoids.nl/hs-fs/hubfs/lung-cancer.png?width=180&name=lung-cancer.png) #### Lung cancer ![pancreatic-cancer](https://resources.huborganoids.nl/hs-fs/hubfs/pancreatic-cancer.png?width=180&name=pancreatic-cancer.png) #### Pancreatic cancer ![pancreatic-cancer](https://www.huborganoids.nl/wp-content/uploads/2023/06/ovarian-cancer.png) #### Ovarian cancer enroll now ## Benchmarked for response to Daraxonrasib Our pan-KRAS PDO panel gives your next-generation inhibitor a defined bar to clear before the clinic. Discover where your compound matches, outperforms, or covers gaps daraxonrasib leaves behind. In a fast-crowding pan-RAS landscape, this head-to-head, patient-relevant benchmarking is what turns a differentiation claim into your defensible preclinical evidence. ![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2026/pill-organoids.png?width=250&name=pill-organoids.png) ![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2026/pdo-screen-icon.png?width=600&name=pdo-screen-icon.png) **EXPERT ANALYSIS** ## Multi-Selective RAS Inhibition: Clinical Validation and Preclinical Implications "The Phase 3 RASolute 302 trial has established clinical proof of concept for multi-selective RAS inhibition. Daraxonrasib, an oral RAS(ON) multi-selective tri-complex inhibitor of the active GTP-bound state of mutant and wild-type RAS, nearly doubled median overall survival relative to standard-of-care chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (13.2 versus 6.7 months), with concurrent improvement in progression-free survival. The trial enrolled 500 patients across 59 sites and included tumors carrying a broad range of RAS variants as well as tumors without an identified RAS mutation. Two features of this result carry direct preclinical consequence. First, the agent addresses G12, G13, and Q61 variants as a class rather than a single allele, and survival benefit was observed irrespective of RAS mutation status. Second, the mechanism is state-dependent rather than pocket-dependent, distinguishing it from the switch-II pocket chemistry underlying approved G12C inhibitors. ### HOW CAN WE HELP *For programs pursuing pan-KRAS, pan-RAS, or RAS(ON) mechanisms, the preclinical requirement is consequently breadth: demonstration of activity across the full allele spectrum, in multiple tumor indications, under standardized assay conditions permitting cross-model comparison. This is the design specification of our PAN-KRAS PDO Screen — a high-throughput platform of 25 PDOs spanning clinically relevant KRAS mutations across colorectal, pancreatic, and lung cancer, benchmarked for response to daraxonrasib, generating comparative efficacy data across indications from a single enrollment."* Yasmine Abouleila, PhD Global Strategic Scientific BD Manager, HUB Organoids enroll in the PAN-KRAS PDO Screen ![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/panel-features.png?width=400&name=panel-features.png) ## Panel features - Representing pivotal KRAS mutants such as **G12D**, **G12C**, **G12V**, **G13D** and many others - **Benchmarked for response to daraxonrasib** across multiple indications to help you guide your next-gen inhibitor and combination startegies - Rigorously characterized, with readily available RNA or DNA sequencing data - Diverse models encompassing both **primary** and **metastatic** tumors request access to panel ![](https://resources.huborganoids.nl/hs-fs/hubfs/assets2024/screening-capabilities.png?width=400&name=screening-capabilities.png) ## Advanced screening capabilities - Direct measurement of cell viability with an image-based viability readout - High-throughput 3D assay format - Test as many compound(s) as you want - No minimum number of models to enroll - High-data quality with 10-point dose-response curves per compound - Inclusive of IC50 determination and IC50 heatmap and synergy maps generation enroll now ## Proven Impact Our meticulously designed KRASmut panel was instrumental in developing the first-ever clinical candidate using organoid technology, targeting head & neck cancer ![](https://resources.huborganoids.nl/hubfs/from-early-discovery-to-clinical-trials.webp) [read case study](https://resources.huborganoids.nl/case-study-drug-discovery-to-clinical-trials-in-five-years) UNIQUE MODELS ## Adagrasib and daraxonrasib induced resistant PDOs available to include in your screen Overcome resistance before it emerges in the clinic ![](https://www.huborganoids.nl/wp-content/uploads/2022/09/preclinical-drug-development.png) book your screen ## Accelerate your KRAS drug development with our comprehensive portfolio ![lead identification](https://resources.huborganoids.nl/hubfs/assets2024/lead-idenitification-icon.png) ![lead identification](https://resources.huborganoids.nl/hubfs/assets2024/lead-idenitification-icon-white.png) **Identify promising leads** ![Benchmarking with standard of care](https://resources.huborganoids.nl/hubfs/assets2024/benchmarking-icon.png) ![Benchmarking with standard of care](https://resources.huborganoids.nl/hubfs/assets2024/benchmarking-icon-white.png) Benchmark against standard of care ![Mode of action studies](https://resources.huborganoids.nl/hubfs/assets2024/mode-of-action-icon.png) ![Mode of action studies](https://resources.huborganoids.nl/hubfs/assets2024/mode-of-action-icon-white.png) Understand the mechanism of action ![Investigate the mechanism of resistance](https://resources.huborganoids.nl/hubfs/assets2024/mechanism-of-resistance-icon.png) ![Investigate the mechanism of resistance](https://resources.huborganoids.nl/hubfs/assets2024/mechanism-of-resistance-icon-white.png) Investigate resistance mechanisms  ![Combination treatment selection](https://resources.huborganoids.nl/hubfs/assets2024/combination-treatment-icon.png) ![Combination treatment selection](https://resources.huborganoids.nl/hubfs/assets2024/combination-treatment-icon-white.png) Craft optimal combination therapy ![Co-clinical biomarker studies](https://resources.huborganoids.nl/hubfs/assets2024/co-clinical-icon.png) ![Co-clinical biomarker studies](https://resources.huborganoids.nl/hubfs/assets2024/co-clinical-icon-white.png) Develop co-clinical biomarker assays ![Companion diagnostics](https://resources.huborganoids.nl/hubfs/assets2024/companion-diagnostics-icon.png) ![Companion diagnostics](https://resources.huborganoids.nl/hubfs/assets2024/companion-diagnostics-icon-white.png) Companion diagnostics partnering [book a consultation](https://www.huborganoids.nl/contact/) ![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids") [Privacy Policy](https://huborganoids.nl/privacy-policy) HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany ***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.* × ### Design your drug screen   × ### Email me KRAS panel info